NYSE:ISR Isoray (ISR) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free ISR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.28▼$0.4252-Week Range N/AVolume145,000 shsAverage Volume290,697 shsMarket Capitalization$54.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Isoray alerts: Email Address Ad Colonial MetalsThe asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.That's why we have released our Free Precious Metals Investment Guide that explains all the details About Isoray Stock (NYSE:ISR)IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.Read More Ad Colonial MetalsThe asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.That's why we have released our Free Precious Metals Investment Guide that explains all the details ISR Stock News HeadlinesNovember 22, 2023 | morningstar.comFrench ISR Label Revamp ReportApril 24, 2023 | thestreet.comWhy IsoRay (ISR) Is Plunging TodayMay 4, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.March 16, 2023 | thestreet.comWhy IsoRay (ISR) Stock Is Surging TodayFebruary 16, 2023 | finance.yahoo.comIsoRay (ISR) Reports Q2 Loss, Misses Revenue EstimatesFebruary 16, 2023 | finance.yahoo.comPerspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022February 8, 2023 | finanznachrichten.deIsoray, Inc.: Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.February 7, 2023 | finance.yahoo.comIsoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.May 4, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.February 6, 2023 | finance.yahoo.comIsoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology MedicineJanuary 30, 2023 | benzinga.comIsoray Announces Results of Fiscal 2023 Annual Meeting of StockholdersJanuary 30, 2023 | finance.yahoo.comIsoray Announces Results of Fiscal 2023 Annual Meeting of StockholdersJanuary 14, 2023 | thestreet.comWhy IsoRay (ISR) Hit a Five-Year High Today (Update)January 12, 2023 | finance.yahoo.comIsoray Announces Adjournment of Annual Meeting of Stockholders to January 27, 2023December 14, 2022 | finance.yahoo.comIsoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2022December 14, 2022 | finance.yahoo.comAMENDED: Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2023December 6, 2022 | proactiveinvestors.comIsoray's merger with Viewpoint Molecular Targeting sets up big opportunity in 2023December 6, 2022 | proactiveinvestors.comIsoray releases Q1 financials as company looks ahead to merger with Viewpoint Molecular TargetingNovember 25, 2022 | finance.yahoo.comIsoray, Inc. (ISR) Stock Historical Prices & Data - Yahoo FinanceNovember 11, 2022 | finanznachrichten.deIsoray, Inc.: Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending MergerNovember 10, 2022 | seekingalpha.comIsoray, Inc. (ISR) Q1 2023 Earnings Call TranscriptNovember 10, 2022 | finance.yahoo.comIsoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending MergerOctober 31, 2022 | finance.yahoo.comIsoray To Announce First Quarter Fiscal 2023 Financial Results on November 10, 2022October 20, 2022 | seekingalpha.comIsoray Stock: Not Going Anywhere Anytime Soon (NYSE:ISR) - Seeking AlphaOctober 18, 2022 | businesswire.comIsoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT - Business WireOctober 18, 2022 | finance.yahoo.comIsoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDTOctober 16, 2022 | benzinga.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMBC, BTRS, ISR, JVA - Isoray (AMEX:ISR), BTRS H - BenzingaSee More Headlines Receive ISR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Isoray and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today5/04/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNYSE:ISR CUSIPN/A CIK728387 Webisoray.com Phone(509) 375-1202Fax509-267-3670EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,270,000.00 Net Margins-115.91% Pretax Margin-91.45% Return on Equity-17.12% Return on Assets-16.15% Debt Debt-to-Equity RatioN/A Current Ratio14.38 Quick Ratio13.99 Sales & Book Value Annual Sales$10.80 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.43 per share Price / BookN/AMiscellaneous Outstanding Shares142,110,000Free Float138,674,000Market Cap$54.57 million OptionableNot Optionable Beta1.48 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesLori A. WoodsChief Executive Officer & DirectorJennifer StreeterChief Operating Officer & VP-Human ResourcesMark J. AustinCo-CFO, Secretary & Chief Accounting OfficerJonathan R. HuntCFO & Principal Financial OfficerWilliam A. CavanaghChief Research & Development OfficerKey CompetitorsIceCure MedicalNASDAQ:ICCMApyx MedicalNASDAQ:APYXHealth Sciences Acquisitions Co. 2NASDAQ:HSAQAutonomix MedicalNASDAQ:AMIXSEP AcquisitionNASDAQ:SEPAView All Competitors ISR Stock Analysis - Frequently Asked Questions How were Isoray's earnings last quarter? Isoray, Inc. (NYSE:ISR) released its earnings results on Wednesday, November, 10th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.01. The business had revenue of $2.56 million for the quarter, compared to analysts' expectations of $2.58 million. Isoray had a negative trailing twelve-month return on equity of 17.12% and a negative net margin of 115.91%. This page (NYSE:ISR) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCould Your Accounts Be Frozen?Allegiance GoldFW: 234x GainWeiss RatingsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Isoray, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.